PressMay 15, 2024 Filament Health Announces First Quarter 2024 Financial Results and Operational Highlights
PressMay 15, 2024 atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
PressMay 15, 2024 PharmaDrug’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
PressMay 14, 2024 Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
PressMay 14, 2024 Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
PressMay 13, 2024 PharmaDrug Provides Forward Plan to Move Its Patent Pending Process and Formulation of Pharmaceutical Grade Biosynthetic Cocaine Through Development into Commercialization
PressMay 13, 2024 AbbVie (ABBV) and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
PressMay 10, 2024 Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
PressMay 9, 2024 New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
PressMay 9, 2024 Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University’s Institute for Psychedelic Research
PressMay 8, 2024 Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
